Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Partnerships 17
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Licensing Agreements 47
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Equity Offering 66
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Asset Transactions 75
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Acquisition 77
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd – Key Competitors 88
Otsuka Pharmaceutical Co Ltd – Key Employees 89
Otsuka Pharmaceutical Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Joint Venture 95
Recent Developments 96
Government and Public Interest 96
Jun 06, 2016: GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com 96
Product News 98
May 09, 2016: Introducing Three New Flavors of Calorie Mate Jelly Focusing on the Need for a Nutritionally Balanced Jelly Beverage Option 98
01/07/2016: Neurovance Appoints Jeff Bailey to Chair Its Board of Directors 99
Clinical Trials 100
Jul 27, 2016: Neurovance Announces Positive Centanafadine Phase 2b Results for Adult ADHD, and Plans for Phase 3 Trials 100
Jan 07, 2016: Neurovance Announces Series of Three Clinical Trials to Support Advanced Development of Centanafadine (CTN) in Adult ADHD 101
Appendix 102
Methodology 102
About GlobalData 102
Contact Us 102
Disclaimer 102
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Otsuka Pharmaceutical Co Ltd, Deals By Therapy Area, 2011 to YTD 2017 10
Otsuka Pharmaceutical Co Ltd, Medical Devices Deals, 2011 to YTD 2017 11
Otsuka Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12
Ribomic Enters into Agreement with Seikagaku 17
Medibio Enters into Agreement with Otsuka Pharma 18
Ribomic Enters into Research Agreement with Astellas Pharma 19
Ribomic Enters into Research Agreement with Evec 20
Cambridge Isotope Laboratories Enters into Agreement with IROA Technologies 21
Otsuka Pharma Enters into Co-Development Agreement with NEC 22
RIKEN and Otsuka Pharma Forms Joint Venture 23
Earth Chemical to Enter into Agreement with Taiko Pharma 24
Astex Pharma Enters into Agreement with Genentech 25
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 26
Ribomic Extends Research Agreement with Otsuka Pharma 28
Probi Enters into Co-Marketing Agreement with Pharmavite 29
Horizon Discovery Enters into Development and Commercialization Agreement with Otsuka Pharma 30
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 31
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma For Lu AF20513 32
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 33
Avanir Pharma Enters Into Agreement With Merck To Promote Diabetes Drugs 34
Otsuka Pharma Enters Into Co-Promotion Agreement Lundbeck For Abilify 36
Otsuka Pharma Forms Joint Venture With Abdi Ibrahim To Market Otsuka’s Drugs In Turkey 37
Astex Pharma, Cancer Research Technology And Newcastle University Enter Into Drug Discovery Agreement 38
Astex Pharma, Cancer Research Technology And Institute of Cancer Research Enter Into Epigenetic Drug Discovery Agreement 40
Otsuka Pharma Amends Co-Development Agreement With UCB 42
Lundbeck Enters Into Co-Development Agreement With Otsuka Pharma 44
Proteros Biostructures Enters Into Drug Discovery Agreement With SuperGen 46
Mylan Pharma Enters into Licensing Agreement with Otsuka Novel Products for Delamanid 47
R-Pharm Enters into Licensing Agreement with Otsuka Novel Products 48
Otsuka Pharma Enters into Licensing Agreement with Teva Pharma for TEV-48125 49
Otsuka Pharma to Enter into Licensing Agreement with Ribomic for RBM001 50
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics for Vadadustat 51
Otsuka Pharma Enters into Licensing Agreement with Akebia Therapeutics 53
Otsuka Pharma Enters into Licensing Agreement with Takara Bio 54
Medimetriks Pharma Enters into Licensing Agreement with Otsuka Pharma for OPA-15406 55
Fujimoto Pharma Enters into Licensing Agreement with Ribomic 56
Lundbeck Enters Into Licensing Agreement With Otsuka Pharma For Lu AE58054 57
Concert Pharma Enters Into Licensing Agreement With AVANIR Pharma For Neurology And Psychiatry Drugs 58
NuView Life Sciences Enters into Licensing Agreement with Otsuka Pharma for VPAC1 Biomarker 60
Otsuka Pharma Enters Into Licensing Agreement With Eisai 61
Avanir Pharma And OptiNose Enter Into Licensing Agreement For Treatment Of Acute Migraine 62
Proteus Biomedical Enters Into Licensing Agreement With Otsuka Pharma 64
Otsuka Pharma Enters Into Licensing Agreement With Kyowa Hakko Kirin For Saxagliptin 65
Taiko Pharma to Raise Funds through Private Placement of Shares 66
Avanir Pharma Raises USD230 Million in Public Offering of Shares 67
Ribomic Raises USD26 Million in IPO of Shares 69
GlycoNex Announces Private Placement Of Shares For US$9.2 Million 70
Avanir Pharma Files Registration Statement For Public Offering Of Securities For Up To US$150 Million 71
Avanir Pharma Increases Size Of Private Placement Of Shares For US$80 Million 72
Astex Pharma Files Registration Statement For Public Offering Of Securities For US$200 Million 73
Tolero Pharma Acquires Drug Development Assets From Astex Pharma 75
Otsuka Pharma to Acquire Neurovance 77
Otsuka Acquires Avanir Pharma for USD3.5 Billion 78
Egypt Otsuka Pharmaceutical to Acquire 80% Stake in Ateco Pharma 80
Otsuka Pharma Completes Acquisition Of Astex Pharma For US$886 Million 81
Gimv Sells Stake In Astex Therapeutics 83
China Otsuka Pharmaceutical Acquires Dalian Taihua Pharmaceutical 84
SuperGen Completes Acquisition Of Astex Therapeutics 85
Otsuka Pharmaceutical Co Ltd, Key Competitors 88
Otsuka Pharmaceutical Co Ltd, Key Employees 89
Otsuka Pharmaceutical Co Ltd, Other Locations 90
Otsuka Pharmaceutical Co Ltd, Subsidiaries 90
Otsuka Pharmaceutical Co Ltd, Joint Venture 95
【免責事項】
http://www.globalresearch.jp/disclaimer